



International  
Vaccine  
Institute

# Developing Countries Vaccine Manufacturers Network







Annual General Meeting  
19 to 21 September 2023  
Cape Town South Africa

Sushant Sahastrabuddhe  
Deputy Director General (Acting)  
Clinical, Assessment, Regulatory, Evaluation (CARE)





# IVI Vaccines Bring *Affordable* Innovation to Global Health

	Cost	Funder	Manufacturer
 <p>Vaccine #1 <b>Oral cholera vaccine</b></p>	Cost thru PQ: <b>\$28M</b>		 Shanchol PQ 2011 Euvichol PQ 2016 Euvichol Plus PQ 2018
 <p>Vaccine #2 <b>Vi-DT TCV (Typhoid)</b></p>	Cost thru PQ <sup>1</sup> : <b>\$29M</b>		 Approved by KMFDS, WHO submitted
 <p>Vaccine #3 <b>Non-typhoidal Salmonella Shigella</b></p>	IVI internal invest. preclinical POC; Wellcome: <b>\$3.2M</b>		 Approved by PBOM

IVI's model of market access:

- Affordability (global access requirements)
- Work with global, regional and local entities
- Facilitation with data generation (surveillance, economics, impact assessment, clinical)
- Advocacy and coordination: GTFCC, PDVI, DVI
- Collaboration and technology transfer for local access
- Innovative technologies to reach the last-mile (MAP)

1. Estimated